Study shows that gene signature identifies high-risk patients with early-stage NSCLC

Researchers have shown that testing for a specific collection of genes in early-stage non-small-cell lung cancer (NSCLC) tissue accurately predicts prognosis. The 15-gene signature appears to have promising potential to identify patients with NSCLC who may or may not benefit from adjuvant chemotherapy. The results reflect advances in developing more personalized approaches to the treatment of NSCLC. Surgical resection is the standard of care for early-stage (stage I and II) NSCLC, and adjuvant chemotherapy is typically used for patients with stage II NSCLC and in only some cases of stage IB disease with a primary tumor larger than 4 cm.…
View More/Source Article